Self-swabbing versus assisted swabbing for viral detection by qRT-PCR: the experience from SARS-CoV-2 based on a meta-analysis of six prospectively designed evaluations conducted in a UK setting.

Publication date: Aug 01, 2024

In April 2020, the UK Government implemented NHS Test and Trace to provide SARS-CoV-2 quantitative reverse transcription polymerase chain reaction (qRT-PCR) testing for the public, with nose-and-throat swabbing for samples performed by trained staff. Self-swabbing (SS) would allow rapid scale-up of testing capacity and access. Six studies were undertaken to determine whether SS was as effective for detecting SARS-CoV-2 as swabbing performed by trained staff. Six prospective studies were conducted between April-October 2020, using six swab/media combinations. Differences between assisted swabbing (AS) and SS were evaluated for concordance, positivity, sensitivity, cycle threshold (Ct) values and void rates. Statistical analysis was performed using 95% confidence intervals (CIs), paired t-tests and model-based methods. Overall, 3,253 individuals were recruited (median age 37 years, 49% female), with 2,933 having valid paired qRT-PCR results. Pooled concordance rate was 98% (95% CI: 96%, 99%). Positivity rate differences for SS (8. 1%) and AS (8. 4%) and differences in pooled sensitivities between SS (86%; 95% CI: 78%, 92%) and AS (91%; 95% CI: 78%, 96%) were nonsignificant. Both types of swabbing led to pooled void rates below 2% and strongly correlated Ct values. Age, sex and previous swabbing experience did not have a significant impact on concordance or sensitivity. The UK adopted a policy to promote self-testing for SARS-CoV-2 based on data demonstrating equivalence of SS versus AS. Positive outcomes with SS are likely generalisable to testing for other respiratory pathogens, and we consider self-sampling and self-testing essential for future pandemic preparedness.

Open Access PDF

Concepts Keywords
Pandemic Adolescent
Pcr Adult
Viral Aged
Child
COVID-19
COVID-19
COVID-19 Testing
Female
Humans
Male
Middle Aged
Nose
PCR
Pharynx
Prospective Studies
SARS-CoV-2
Self-swabbing
Self-testing
Sensitivity and Specificity
Specimen Handling
Testing programme
United Kingdom
United Kingdom
Young Adult

Semantics

Type Source Name
disease VO nose
drug DRUGBANK Etoperidone
disease VO effective
disease VO age
disease MESH Infectious Diseases
disease MESH Infections
disease MESH COVID 19
disease MESH severe acute respiratory syndrome
drug DRUGBANK Ademetionine
drug DRUGBANK Serine
disease VO time
disease VO device
drug DRUGBANK Coenzyme M
disease VO manufacturer
disease IDO site
disease VO volume
disease VO data set
drug DRUGBANK Crofelemer
disease VO Iss
drug DRUGBANK Indoleacetic acid
disease VO population
drug DRUGBANK Ilex paraguariensis leaf
disease MESH syndrome
disease VO USA
disease IDO process
disease VO viable
disease MESH uncertainty
drug DRUGBANK Trestolone
disease IDO infectivity
drug DRUGBANK Cysteamine
drug DRUGBANK Mexiletine
disease VO company
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH influenza
disease IDO intervention
disease IDO facility
disease VO Severe acute respiratory syndrome coronavirus 2

Original Article

(Visited 2 times, 1 visits today)